Nuvation Bio Inc. (NYSE:NUVB) Given Consensus Recommendation of “Moderate Buy” by Analysts

Nuvation Bio Inc. (NYSE:NUVB) has earned an average rating of “Moderate Buy” from the eleven brokerages that are currently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $12.50.

NUVB has been the subject of a number of recent research reports. Zacks Research cut shares of Nuvation Bio from a “hold” rating to a “strong sell” rating in a research report on Tuesday, May 26th. UBS Group reduced their target price on shares of Nuvation Bio from $10.00 to $7.00 and set a “neutral” rating for the company in a research report on Tuesday, March 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Nuvation Bio in a research report on Tuesday, April 21st. HC Wainwright reissued a “buy” rating and issued a $17.00 target price on shares of Nuvation Bio in a research report on Tuesday, May 5th. Finally, Wedbush reissued an “outperform” rating and issued a $11.00 target price on shares of Nuvation Bio in a research report on Tuesday, May 5th.

Nuvation Bio Trading Down 3.8%

NUVB stock opened at $4.72 on Thursday. The company has a fifty day moving average price of $4.65 and a two-hundred day moving average price of $5.93. The stock has a market cap of $1.64 billion, a price-to-earnings ratio of -10.96 and a beta of 1.52. Nuvation Bio has a one year low of $1.57 and a one year high of $9.75. The company has a debt-to-equity ratio of 0.15, a current ratio of 7.44 and a quick ratio of 7.24.

Nuvation Bio (NYSE:NUVB) last announced its earnings results on Monday, May 4th. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.04. The company had revenue of $83.23 million during the quarter, compared to analysts’ expectations of $66.22 million. Nuvation Bio had a negative net margin of 102.06% and a negative return on equity of 44.10%. Equities analysts anticipate that Nuvation Bio will post -0.64 EPS for the current year.

Insider Activity

In related news, insider Dongfang Liu sold 50,000 shares of the company’s stock in a transaction dated Friday, April 17th. The shares were sold at an average price of $5.02, for a total transaction of $251,000.00. Following the completion of the sale, the insider owned 18,000 shares of the company’s stock, valued at $90,360. This represents a 73.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kerry Wentworth sold 36,750 shares of the company’s stock in a transaction dated Friday, April 17th. The stock was sold at an average price of $5.01, for a total transaction of $184,117.50. Following the sale, the insider directly owned 53,000 shares of the company’s stock, valued at $265,530. This represents a 40.95% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 286,750 shares of company stock valued at $1,339,118 in the last ninety days. 30.11% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Nuvation Bio

Several institutional investors and hedge funds have recently bought and sold shares of the company. NewEdge Advisors LLC lifted its position in Nuvation Bio by 8.3% during the first quarter. NewEdge Advisors LLC now owns 1,031,112 shares of the company’s stock worth $4,423,000 after purchasing an additional 78,946 shares during the period. Tanaka Capital Management Inc. raised its stake in Nuvation Bio by 7.2% during the first quarter. Tanaka Capital Management Inc. now owns 901,825 shares of the company’s stock worth $3,869,000 after acquiring an additional 60,220 shares in the last quarter. ADAR1 Capital Management LLC acquired a new position in Nuvation Bio during the first quarter worth about $187,000. Amundi increased its stake in shares of Nuvation Bio by 181.5% in the first quarter. Amundi now owns 36,072 shares of the company’s stock valued at $155,000 after buying an additional 23,258 shares during the period. Finally, California State Teachers Retirement System increased its stake in shares of Nuvation Bio by 42.2% in the first quarter. California State Teachers Retirement System now owns 303,784 shares of the company’s stock valued at $1,303,000 after buying an additional 90,114 shares during the period. Institutional investors own 61.67% of the company’s stock.

About Nuvation Bio

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.